Autolus' Blood Cancer CAR T-Cell Therapy Receives Promising Innovative Medicine In UK

by Vandana Singh, Benzinga Editor

August 9, 2021 11:57 AM | 28 seconds read | Make a Comment

The U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has granted Promising Innovative Medicine (PIM) designation to Autolus Therapeutics plc's AUTL AUTO1 (obecabtagene autoleucel, obe-cel).
The Company's CAR T cell therapy is being investigated in the ongoing FELIX Phase 1b/2 study in relapsed/refractory adult B-cell Acute Lymphocytic Leukemia (ALL) in patients 18 years and older.
Price Action: AUTL shares are up 5.11% at $6.38 during the market session on the last check Monday.
Related content: Benzinga's Full FDA Calendar.

Posted In: Biotech News Health Care Small Cap FDA Movers Trading Ideas General Briefs T-cell

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.